Fate Therapeutics - FATE Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $10.44
Forecasted Upside: 365.96%
Number of Analysts: 20
Breakdown:
2 Sell Ratings
13 Hold Ratings
5 Buy Ratings
0 Strong Buy Ratings

^$2.24 As of 12/8/2023 01:00 AM ET

▼ -0.11 (-4.68%)

1 month | 3 months | 12 months

Get New Fate Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for FATE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FATE

^$10.44

▲ +365.96% Upside Potential

This price target is based on 20 analysts offering 12 month price targets for Fate Therapeutics in the last 3 months. The average price target is $10.44, with a high forecast of $65.00 and a low forecast of $3.00. The average price target represents a 365.96% upside from the last price of $2.24.

Current Consensus is Hold

The current consensus among 20 contributing investment analysts is to hold stock in Fate Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
5 buy ratings
13 hold ratings
2 sell ratings

Ratings as of

6/16/2022

0 strong buy ratings
5 buy ratings
13 hold ratings
2 sell ratings

Ratings as of

9/14/2022

0 strong buy ratings
5 buy ratings
13 hold ratings
2 sell ratings

Ratings as of

12/13/2022

0 strong buy ratings
5 buy ratings
13 hold ratings
2 sell ratings

Ratings as of

3/13/2023

0 strong buy ratings
5 buy ratings
13 hold ratings
2 sell ratings

Ratings as of

6/11/2023

0 strong buy ratings
5 buy ratings
13 hold ratings
2 sell ratings

Ratings as of

9/9/2023

0 strong buy ratings
5 buy ratings
13 hold ratings
2 sell ratings

Ratings as of

11/8/2023

0 strong buy ratings
5 buy ratings
13 hold ratings
2 sell ratings

Ratings as of

12/8/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
11/20/2023	Mizuho	Lower Target	Buy ➝ Buy	$12.00 ➝ $8.00	Low
11/13/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$5.00 ➝ $3.00	Low
11/9/2023	BMO Capital Markets	Boost Target	Market Perform ➝ Market Perform	$5.40 ➝ $6.00	Low
11/9/2023	Wedbush	Reiterated Rating	Neutral ➝ Neutral	$6.00 ➝ $3.00	Low
11/9/2023	Wells Fargo & Company	Lower Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $5.00	Low
9/7/2023	Cantor Fitzgerald	Reiterated Rating	Neutral ➝ Neutral	$5.00	Low
8/16/2023	Truist Financial	Reiterated Rating	Hold ➝ Hold	$7.00	Low
8/10/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00	Low
8/10/2023	Barclays	Lower Target	Overweight ➝ Overweight	$12.00 ➝ $6.00	Low
8/9/2023	BMO Capital Markets	Lower Target	Market Perform ➝ Market Perform	$6.00 ➝ $5.40	Low
5/4/2023	Stifel Nicolaus	Lower Target		$5.30 ➝ $5.00	Low
5/4/2023	Cantor Fitzgerald	Lower Target		$8.00 ➝ $5.00	Low
3/27/2023	Wells Fargo & Company	Reiterated Rating	Equal Weight	$6.00	Low
3/2/2023	Citigroup	Boost Target	Buy	$9.00 ➝ $10.00	Low
3/1/2023	EF Hutton Acquisition Co. I	Reiterated Rating	Buy	$10.00	Low
3/1/2023	Piper Sandler	Lower Target		$12.00 ➝ $7.00	Low
1/24/2023	HC Wainwright	Downgrade	Buy ➝ Neutral	$115.00 ➝ $7.00	Low
1/9/2023	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral		Low
1/6/2023	Morgan Stanley	Lower Target	Equal Weight	$35.00 ➝ $8.00	N/A
1/6/2023	Cowen	Downgrade	Outperform ➝ Market Perform		N/A
1/6/2023	Truist Financial	Reiterated Rating	Buy ➝ Hold	$46.00 ➝ $7.00	N/A
1/6/2023	SVB Leerink	Lower Target	Outperform	$62.00 ➝ $10.00	N/A
1/6/2023	Bank of America	Downgrade	Buy ➝ Underperform		N/A
1/6/2023	Wedbush	Downgrade	Outperform ➝ Neutral	$42.00 ➝ $7.00	N/A
1/6/2023	Stifel Nicolaus	Downgrade	Buy ➝ Hold		N/A
1/6/2023	Cowen	Downgrade	Outperform ➝ Market Perform		N/A
1/6/2023	Piper Sandler	Downgrade	Overweight ➝ Neutral	$71.00 ➝ $12.00	N/A
1/6/2023	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$20.00 ➝ $7.00	N/A
1/5/2023	EF Hutton Acquisition Co. I	Initiated Coverage	Buy	$16.00	Low
1/3/2023	Guggenheim	Downgrade	Buy ➝ Neutral		Low
12/22/2022	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Low
12/15/2022	The Goldman Sachs Group	Initiated Coverage	Sell	$10.00	Low
12/13/2022	Truist Financial	Lower Target	Buy	$51.00 ➝ $46.00	Low
12/13/2022	SVB Leerink	Lower Target	Outperform	$64.00 ➝ $62.00	Low
12/12/2022	Oppenheimer	Lower Target		$90.00 ➝ $65.00	Low
11/24/2022	SVB Leerink	Set Target		$64.00	Low
11/16/2022	Citigroup	Lower Target	Buy	$87.00 ➝ $80.00	Low
11/4/2022	Cantor Fitzgerald	Reiterated Rating	Overweight	$98.00 ➝ $45.00	N/A
10/10/2022	Canaccord Genuity Group	Initiated Coverage	Buy	$42.00	Low
9/21/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
9/9/2022	Morgan Stanley	Lower Target	Equal Weight	$45.00 ➝ $35.00	Low
8/18/2022	Wells Fargo & Company	Reiterated Rating	Overweight	$90.00	Low
8/4/2022	Oppenheimer	Lower Target		$135.00 ➝ $90.00	Low
7/28/2022	Needham & Company LLC	Initiated Coverage	Hold		Low
7/11/2022	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$50.00 ➝ $47.00	N/A
6/2/2022	Robert W. Baird	Initiated Coverage	Neutral	$28.00	Low
5/23/2022	Piper Sandler	Lower Target	Overweight	$113.00 ➝ $71.00	Medium
4/13/2022	Truist Financial	Lower Target		$125.00 ➝ $75.00	High
4/1/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		N/A
3/4/2022	HC Wainwright	Lower Target	Buy	$122.00 ➝ $115.00	Low
3/1/2022	Wedbush	Boost Target	Outperform	$74.00 ➝ $77.00	Medium
1/11/2022	HC Wainwright	Reiterated Rating	Buy	$122.00	High
1/3/2022	Guggenheim	Lower Target		$107.00 ➝ $78.00	Medium
12/15/2021	Morgan Stanley	Lower Target	Equal Weight	$74.00 ➝ $62.00	High
12/15/2021	HC Wainwright	Boost Target	Buy	$121.00 ➝ $122.00	High
12/15/2021	Wedbush	Upgrade	Neutral ➝ Outperform	$71.00 ➝ $74.00	High
12/7/2021	Cowen	Initiated Coverage	Outperform		High
11/8/2021	Citigroup	Upgrade	Neutral ➝ Buy	$94.00 ➝ $87.00	Medium
11/8/2021	SVB Leerink	Lower Target	Outperform	$118.00 ➝ $115.00	Medium
11/5/2021	Roth Capital	Lower Target	Neutral	$90.00 ➝ $60.00	High
8/26/2021	Morgan Stanley	Initiated Coverage	Equal Weight	$77.00	Low
8/23/2021	HC Wainwright	Reiterated Rating	Buy	$121.00	Medium
8/5/2021	HC Wainwright	Boost Target	Buy	$120.00 ➝ $121.00	High
8/5/2021	SVB Leerink	Lower Target	Outperform	$120.00 ➝ $118.00	High
7/9/2021	Stifel Nicolaus	Reiterated Rating	Buy	$116.00	High
6/7/2021	HC Wainwright	Upgrade	Neutral ➝ Buy	$120.00	High
5/14/2021	Wedbush	Downgrade	Outperform ➝ Neutral		Medium
5/7/2021	Wedbush	Upgrade	Neutral ➝ Outperform	$88.00	Low
4/26/2021	Jefferies Financial Group	Initiated Coverage	Buy	$145.00	Low
3/12/2021	SVB Leerink	Boost Target	Outperform	$58.00 ➝ $121.00	Medium
3/4/2021	Wedbush	Reiterated Rating	Outperform ➝ Neutral		High
3/4/2021	Wells Fargo & Company	Boost Target	Overweight	$84.00 ➝ $130.00	N/A
2/26/2021	Truist Financial	Boost Target		$85.00 ➝ $135.00	Medium
2/26/2021	Bank of America	Initiated Coverage	Buy	$115.00	High
2/26/2021	Wedbush	Downgrade	Outperform ➝ Neutral		High
2/25/2021	Roth Capital	Boost Target		$30.00 ➝ $90.00	High
2/25/2021	Cantor Fitzgerald	Boost Target	Overweight	$86.00 ➝ $98.00	High
2/25/2021	Mizuho	Boost Target	Buy	$88.00 ➝ $109.00	High
2/17/2021	Piper Sandler	Boost Target	Overweight	$99.00 ➝ $116.00	Low
2/11/2021	Citigroup	Downgrade	Buy ➝ Neutral		Low
1/27/2021	HC Wainwright	Reiterated Rating	Neutral	$108.00	Medium
1/25/2021	BMO Capital Markets	Boost Target	Market Perform	$57.00 ➝ $88.00	Medium
1/19/2021	Oppenheimer	Reiterated Rating	Outperform	$70.00 ➝ $135.00	High
1/15/2021	Barclays	Boost Target	Positive ➝ Overweight	$110.00 ➝ $130.00	High
12/21/2020	Stifel Nicolaus	Boost Target	Buy	$79.00 ➝ $118.00	High
12/17/2020	Barclays	Boost Target	Overweight	$80.00 ➝ $110.00	Low
12/8/2020	Mizuho	Boost Target	Buy	$40.00 ➝ $88.00	High
12/7/2020	BMO Capital Markets	Boost Target	Market Perform	$43.00 ➝ $57.00	High
12/7/2020	Wells Fargo & Company	Boost Target	Overweight	$61.00 ➝ $84.00	High
12/7/2020	Wedbush	Boost Target	Outperform	$55.00 ➝ $88.00	High
12/7/2020	Smith Barney Citigroup	Boost Target		$63.00 ➝ $76.00	High
12/7/2020	Piper Sandler	Boost Target	Overweight	$71.00 ➝ $99.00	High
12/7/2020	Oppenheimer	Boost Target	Outperform	$60.00 ➝ $70.00	High
12/7/2020	SVB Leerink	Boost Target	Outperform	$34.00 ➝ $58.00	High
12/2/2020	Barclays	Boost Target	Overweight	$60.00 ➝ $70.00	Low
11/24/2020	Truist Financial	Boost Target		$40.00 ➝ $65.00	Low
11/9/2020	Smith Barney Citigroup	Boost Target		$40.00 ➝ $63.00	Low
11/8/2020	Oppenheimer	Boost Target	Outperform	$40.00 ➝ $60.00	High
11/6/2020	Piper Sandler	Boost Target	Overweight	$59.00 ➝ $71.00	Low
11/6/2020	Wells Fargo & Company	Boost Target	Overweight	$38.00 ➝ $61.00	High
11/6/2020	BMO Capital Markets	Boost Target	Market Perform	$29.00 ➝ $43.00	High
10/15/2020	Barclays	Boost Target	Overweight	$40.00 ➝ $60.00	High
8/13/2020	Cantor Fitzgerald	Boost Target	Overweight	$32.00 ➝ $40.00	Low
8/6/2020	HC Wainwright	Reiterated Rating	Buy	$42.00	Medium
8/6/2020	Oppenheimer	Reiterated Rating	Buy	$40.00	High
6/9/2020	Oppenheimer	Initiated Coverage	Buy	$34.00 ➝ $40.00	Low
6/9/2020	Piper Sandler	Lower Target		$63.00 ➝ $59.00	Low
5/13/2020	HC Wainwright	Initiated Coverage	Buy	$42.00	High
5/12/2020	BMO Capital Markets	Boost Target	Market Perform	$28.00 ➝ $29.00	High
4/6/2020	Oppenheimer	Lower Target	Outperform	$36.00 ➝ $34.00	Low
4/3/2020	Piper Sandler	Boost Target			High
4/3/2020	Wedbush	Boost Target	Outperform	$38.00 ➝ $41.00	High
4/3/2020	Mizuho	Reiterated Rating	Buy	$40.00	High
3/4/2020	Citigroup	Boost Target	Buy	$26.00 ➝ $41.00	High
3/4/2020	Barclays	Initiated Coverage	Overweight	$40.00	High
3/3/2020	BMO Capital Markets	Boost Target		$22.00 ➝ $28.00	High
3/3/2020	Roth Capital	Boost Target		$20.00 ➝ $30.00	High
3/3/2020	BTIG Research	Boost Target	Buy	$27.00 ➝ $42.00	High
3/3/2020	Piper Sandler	Boost Target	Overweight	$28.00 ➝ $57.00	High
3/3/2020	Guggenheim	Boost Target	Buy	$25.00 ➝ $41.00	High
3/3/2020	Oppenheimer	Boost Target	Outperform	$27.00 ➝ $36.00	High
2/26/2020	Mizuho	Boost Target	Buy	$33.00 ➝ $40.00	High
2/14/2020	Wedbush	Boost Target	Outperform	$29.00 ➝ $33.00	Medium
2/12/2020	Wells Fargo & Company	Reiterated Rating	Overweight	$24.00 ➝ $34.00	High
1/9/2020	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$22.00	High
12/30/2019	Mizuho	Boost Target	Buy ➝ Buy	$27.00 ➝ $33.00	High
12/9/2019	Oppenheimer	Reiterated Rating	Buy	$27.00	High
12/9/2019	BMO Capital Markets	Lower Target	Outperform	$26.00 ➝ $22.00	High
12/9/2019	Wells Fargo & Company	Upgrade	Market Perform ➝ Outperform	$24.00	High
11/12/2019	SunTrust Banks	Initiated Coverage	Buy	$25.00	Low
11/6/2019	Mizuho	Downgrade	Buy		High
11/6/2019	Wells Fargo & Company	Downgrade	Outperform ➝ Market Perform	$24.00 ➝ $16.00	High
9/30/2019	Stifel Nicolaus	Initiated Coverage	Buy	$27.00	High
9/16/2019	Piper Sandler Companies	Lower Target	Overweight	$30.00 ➝ $28.00	Low
9/4/2019	Mizuho	Reiterated Rating	Buy	$27.00	High
8/9/2019	BTIG Research	Initiated Coverage	Buy ➝ Buy	$27.00	High
8/7/2019	BMO Capital Markets	Set Target	Buy	$27.00	High
8/7/2019	Wedbush	Boost Target	Outperform	$21.00 ➝ $26.00	High
7/22/2019	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$32.00 ➝ $32.00	High
7/12/2019	CIBC	Initiated Coverage	Outperform ➝ Outperform	$27.00	High
7/12/2019	Oppenheimer	Initiated Coverage	Outperform	$27.00 ➝ $27.00	High
6/27/2019	Piper Sandler Companies	Boost Target	Overweight ➝ Top Pick	$23.00 ➝ $30.00	High
6/12/2019	Mizuho	Initiated Coverage	Buy ➝ Buy	$27.00	High
6/7/2019	Roth Capital	Initiated Coverage	Neutral ➝ Neutral	$20.00 ➝ $20.00	Medium
5/30/2019	Guggenheim	Initiated Coverage	Buy	$25.00	High
5/24/2019	Citigroup	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $26.00	Low
3/28/2019	SVB Leerink	Initiated Coverage	Outperform	$20.00	Medium
3/6/2019	Wells Fargo & Company	Boost Target	Outperform	$18.00 ➝ $24.00	High
2/11/2019	Wedbush	Boost Target	Outperform ➝ Outperform	$19.00 ➝ $21.00	Low
1/3/2019	Stephens	Downgrade	Overweight ➝ Equal		Medium

(Data available from 12/9/2018 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

9 very positive mentions
15 positive mentions
2 negative mentions
2 very negative mentions

Mentions as of

5/13/2023

1 very positive mentions
7 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

6/12/2023

3 very positive mentions
1 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

7/12/2023

1 very positive mentions
4 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

8/11/2023

7 very positive mentions
6 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/10/2023

2 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/10/2023

1 very positive mentions
2 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

11/9/2023

1 very positive mentions
6 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

12/9/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

finance.yahoo.com
11/9/2023
FATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/Y

Negative

No negative mentions tracked during this time.

Positive

seekingalpha.com
11/12/2023
Fate Therapeutics: Getting There, But Perpetually
morningstar.com
11/12/2023
Fate Therapeutics Inc FATE
markets.businessinsider.com
11/9/2023
TD Cowen Keeps Their Hold Rating on Fate Therapeutics (FATE)
finance.yahoo.com
11/9/2023
Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2023 Earnings Call Transcript
msn.com
11/9/2023
Fate Therapeutics files $300M mixed securities shelf

Very Positive

markets.businessinsider.com
11/10/2023
Fate Therapeutics: Promising Developments and Buy Rating Justified by Clinical Trials and Financial Standing

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Today's Range

Now: $2.24

$2.24

$2.41

50 Day Range

MA: $2.13

$1.65

$2.65

52 Week Range

Now: $2.24

$1.63

$19.57

Volume

783,716 shs

Average Volume

2,617,866 shs

Market Capitalization

$220.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Fate Therapeutics?: The following equities research analysts have issued research reports on Fate Therapeutics in the last year: Bank of America Co., Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Cowen Inc, Cowen Inc., EF Hutton Acquisition Co. I, Guggenheim, HC Wainwright, Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist Financial Co., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for FATE.
What is the current price target for Fate Therapeutics?: 16 Wall Street analysts have set twelve-month price targets for Fate Therapeutics in the last year. Their average twelve-month price target is $10.44, suggesting a possible upside of 366.0%. Oppenheimer Holdings Inc. has the highest price target set, predicting FATE will reach $65.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $3.00 for Fate Therapeutics in the next year.
View the latest price targets for FATE.
What is the current consensus analyst rating for Fate Therapeutics?: Fate Therapeutics currently has 2 sell ratings, 13 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in FATE, but not buy more shares or sell existing shares.
View the latest ratings for FATE.
What other companies compete with Fate Therapeutics?: Other companies that are similar to Fate Therapeutics include AlloVir, Compass Therapeutics, Fennec Pharmaceuticals, Innate Pharma and SOPHiA GENETICS. Learn More about companies similar to Fate Therapeutics.
How do I contact Fate Therapeutics' investor relations team?: Fate Therapeutics' physical mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company's listed phone number is (858) 875-1800 and its investor relations email address is [email protected]. The official website for Fate Therapeutics is www.fatetherapeutics.com. Learn More about contacing Fate Therapeutics investor relations.

Fate Therapeutics - FATE Stock Price Target and Predictions

Analyst Price Target for FATE

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.22 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Fate Therapeutics?

What is the current price target for Fate Therapeutics?

What is the current consensus analyst rating for Fate Therapeutics?

What other companies compete with Fate Therapeutics?

How do I contact Fate Therapeutics' investor relations team?